United States· US:73141-019_32c1e44a-6ccf-c3c7-e063-6394a90ad7fc

Guanfacine

A guanfacine product containing guanfacine hydrochloride, registered in United States by A2A Integrated Pharmaceuticals. The same ATC class is registered in 14 of our 19 countries.

ATC C02AC02US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedGuanfacineATCC02AC02REGISTER NO.US:73141-019_32c1e44a…PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Guanfacine is registered in 14 of 19 countries.

Countries holding a registration under ATC C02AC02 (guanfacine), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 8 of them publish a price we can compare per daily dose

Guanfacine · ATC C02AC02

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of guanfacine costs, country by country.

Normalised to the WHO defined daily dose (3 mg), the median price runs from $0.21 in United States to $7.74 in Switzerland — a ×37 gap.

  • United States: $0.21 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail

Guanfacine · price per daily dose (3 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$7.74
  • US United States$0.21 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
GUANFACINE HYDROCHLORIDE
Manufacturer
A2A Integrated Pharmaceuticals
Country
United States (US)
ATC code
C02AC02
ATC class
Guanfacine
Defined daily dose
3 mg, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 2

  • ndc11
    73141-019-04
  • ndc11
    7314101904
    100 TABLET in 1 BOTTLE (73141-019-04)

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

163 interactions on record for guanfacine.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Guanfacine · interactions on record

163 records

  • 30 severe
  • 133 moderate

Most severe, free to view

  • AprepitantA04AD12severe
  • DexamethasoneH02AB02severe
  • KetoconazoleH02CA03severe
  • ChloramphenicolJ01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Guanfacine in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All guanfacine products

Authorised across Europe · EMA

The same active substance is authorised in 5 EEA countries. Names it is sold under:

  • Germany · Guanfacin Neuraxpharm
  • United Kingdom (Northern Ireland) · Guanfacine Crescent
  • Iceland · Intuniv, Paxneury
  • Liechtenstein · Intuniv, Paxneury
  • Norway · Intuniv, Paxneury

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a97ea5f5-73ae-4843-a745-f6c21b03260e
GET /v1/drugs/a97ea5f5-73ae-4843-a745-f6c21b03260e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "2",
  "substance": "GUANFACINE HYDROCHLORIDE",
  "productndc": "73141-019",
  "dosage_form": "TABLET",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "ANDA216828",
  "marketing_category": "ANDA"
}

See everything about guanfacine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.